

Andrea Mariani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1013641/publications.pdf>

Version: 2024-02-01

90
papers

4,740
citations

117625

34
h-index

102487

66
g-index

91
all docs

91
docs citations

91
times ranked

4142
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall survival after surgical staging by lymph node dissection versus sentinel lymph node biopsy in endometrial cancer: a national cancer database study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 28-40.	2.5	7
2	Clear cell carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2022, 164, 658-666.	1.4	23
3	Catalogue of the Riga Jesuit College Book Collection (1583-1621). History and Reconstruction of the Collection = R��gas jezua�tu kol���ijas gr��matu kr��juma (1583-1621) katalogs. Kr��juma v��sture un rekonstrukcija. Edited by Gustavs Strenga, Andris Lev��ns; Catalogue edited by Ren��te Berga, Laura Kreigere-Liepi��ta. <i>Zapiski Historyczne</i> . 2022. LXXXVII. 160.	0.0	0
4	Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 85-91.	2.5	27
5	Lumping and splitting: The need for precision medicine and��personomics��in endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e38.	2.2	3
6	Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2020-002217.	2.5	8
7	Fertility-sparing management for endometrial cancer: review of the literature. <i>Minerva Medica</i> , 2021, 112, 55-69.	0.9	34
8	Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 537-544.	2.5	4
9	Sentinel lymph node for endometrial cancer treatment: review of the literature. <i>Minerva Medica</i> , 2021, 112, 70-80.	0.9	13
10	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 647-655.	2.5	28
11	In search for biomarkers and potential drug targets for uterine serous endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1647-1658.	2.5	5
12	The shift from inpatient to outpatient hysterectomy for endometrial cancer in the United States: trends, enabling factors, cost, and safety. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 686-693.	2.5	9
13	Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 702-708.	2.5	6
14	Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer. <i>PLoS ONE</i> , 2021, 16, e0252390.	2.5	5
15	Low-volume lymphatic metastasis (isolated tumor cells) in endometrial cancer: management and prognosis. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1080-1084.	2.5	1
16	Uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, 226-234.	1.4	58
17	Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study. <i>Gynecologic Oncology</i> , 2021, 162, 590-598.	1.4	28
18	Paradigm shifts in gynecologic oncology. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-003108.	2.5	2

#	ARTICLE	IF	CITATIONS
19	Ultrastaging of â€œnegativeâ€™ pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1541-1548.	2.5	1
20	Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 682-688.	1.4	20
21	Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 62-69.	1.4	43
22	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. <i>Gynecologic Oncology</i> , 2020, 156, 147-153.	1.4	61
23	Implementing robotic surgery for uterine cancer in the United States: Better outcomes without increased costs. <i>Gynecologic Oncology</i> , 2020, 156, 451-458.	1.4	27
24	A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 1627-1632.	2.5	16
25	Impact of hysteroscopy on course of disease in high-risk endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1513-1519.	2.5	9
26	A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100574.	0.6	26
27	Signals from the Metastatic Niche Regulate Early and Advanced Ovarian Cancer Metastasis through miR-4454 Downregulation. <i>Molecular Cancer Research</i> , 2020, 18, 1202-1217.	3.4	15
28	External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 797-805.	2.5	11
29	Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 485-490.	2.5	7
30	Being a Doctor Will Never Be the Same After the COVID-19 Pandemic. <i>American Journal of Medicine</i> , 2020, 133, 652.	1.5	16
31	Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 727-732.	0.6	6
32	Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm. <i>Gynecologic Oncology</i> , 2019, 155, 177-185.	1.4	38
33	Factors influencing the adoption of the sentinel lymph node technique for endometrial cancer staging: an international survey of gynecologic oncologists. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 60-67.	2.5	43
34	Genes associated with bowel metastases in ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 495-504.	1.4	40
35	Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells. <i>Gynecologic Oncology</i> , 2019, 153, 670-675.	1.4	62
36	Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome). <i>Scientific Reports</i> , 2019, 9, 19213.	3.3	52

#	ARTICLE	IF	CITATIONS
37	Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 179.e1-179.e10.	1.3	28
38	Are early screening biomarkers for endometrial cancer needed to reduce health disparities?. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 408-409.	1.3	3
39	Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation. <i>JAMA Surgery</i> , 2018, 153, e180141.	4.3	55
40	Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 170-199.	4.9	488
41	VaDiR: an integrated approach to Variant Detection in RNA. <i>GigaScience</i> , 2018, 7, .	6.4	16
42	Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries. <i>Journal of the National Cancer Institute</i> , 2018, 110, 750-757.	6.3	28
43	Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy. <i>Gynecologic Oncology</i> , 2018, 149, 291-296.	1.4	12
44	Reducing the Rate of Minimally Invasive Hysterectomy for Fibroids in Favor of Abdominal Surgeryâ€”There Is Always Something Evil in Good Intentionsâ€”Reply. <i>JAMA Surgery</i> , 2018, 153, 1063.	4.3	0
45	Current landscape and future perspective of sentinel node mapping in endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e94.	2.2	20
46	Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy. <i>Gynecologic Oncology</i> , 2018, 151, 235-242.	1.4	63
47	Case for a role of the microbiome in gynecologic cancers: Clinician's perspective. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 1693-1704.	1.3	24
48	Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 58.	2.8	7
49	Frozen Section for Detection of Lymph Nodes After Cervical Injection with Indocyanine Green (ICG) for Sentinel Lymph Node Technique in Endometrial Cancer Staging. <i>Annals of Surgical Oncology</i> , 2018, 25, 3692-3698.	1.5	17
50	Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. <i>Gynecologic Oncology</i> , 2017, 145, 21-26.	1.4	58
51	Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIc endometrial carcinoma at higher risk for nodal disease. <i>Gynecologic Oncology</i> , 2017, 147, 541-548.	1.4	82
52	Abnormal Uterine Bleeding Is Associated With Increased BMP7 Expression in Human Endometrium. <i>Reproductive Sciences</i> , 2017, 24, 671-681.	2.5	14
53	Inflammatory and Nutritional Serum Markers as Predictors of Peri-operative Morbidity and Survival in Ovarian Cancer. <i>Anticancer Research</i> , 2017, 37, 3673-3677.	1.1	28
54	Primary brain metastases of endometrial cancer: A report of 18 cases and review of the literature. <i>Gynecologic Oncology</i> , 2016, 142, 70-75.	1.4	40

#	ARTICLE	IF	CITATIONS
55	Potential contribution of the uterine microbiome in the development of endometrial cancer. <i>Genome Medicine</i> , 2016, 8, 122.	8.2	246
56	Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 142, 311-316.	1.4	103
57	The role of surgery in recurrent endometrial cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 741-750.	2.4	12
58	The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. <i>Gynecologic Oncology</i> , 2016, 140, 270-276.	1.4	38
59	Incorporating robotic-assisted surgery for endometrial cancer staging: Analysis of morbidity and costs. <i>Gynecologic Oncology</i> , 2016, 141, 218-224.	1.4	75
60	Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. <i>Gynecologic Oncology</i> , 2016, 140, 394-399.	1.4	139
61	Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 140, 15-21.	1.4	80
62	Risk-adjusted outcomes in elderly endometrial cancer patients: Implications of the contrasting impact of age on progression-free and cause-specific survival. <i>Gynecologic Oncology</i> , 2015, 138, 133-140.	1.4	14
63	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. <i>Gynecologic Oncology</i> , 2015, 137, 14-22.	1.4	79
64	Detection of circulating tumor cells in high-risk endometrial cancer. <i>Anticancer Research</i> , 2015, 35, 683-7.	1.1	17
65	Incisional Recurrences After Endometrial Cancer Surgery. <i>Anticancer Research</i> , 2015, 35, 6097-104.	1.1	9
66	Preoperative selection of endometrial cancer patients at low risk for lymph node metastases: useful criteria for enrollment in clinical trials. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 267.	2.2	11
67	Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 133, 485-493.	1.4	64
68	Short-term outcomes after incontinent conduit for gynecologic cancer: Comparison of ileal, sigmoid, and transverse colon. <i>Gynecologic Oncology</i> , 2014, 133, 563-567.	1.4	4
69	Role of pelvic and paraaortic lymphadenectomy in endometrial cancer: Current evidence. <i>Journal of Obstetrics and Gynaecology Research</i> , 2014, 40, 301-311.	1.3	143
70	Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: A histologic dichotomy. <i>Gynecologic Oncology</i> , 2014, 132, 578-584.	1.4	33
71	Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 132, 38-43.	1.4	160
72	Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 71-76.	1.4	8

#	ARTICLE	IF	CITATIONS
73	Conservative Management of Atypical Hyperplasia and Grade I Endometrial Carcinoma: Review of the Literature and Presentation of a Series. <i>Journal of Gynecologic Surgery</i> , 2012, 28, 262-269.	0.1	9
74	Lymphadenectomy in Endometrial Cancer: Which Is the Right Question?. <i>International Journal of Gynecological Cancer</i> , 2010, 20, S52-S54.	2.5	25
75	The role of pelvic and paraaortic lymph node dissection in the surgical treatment of endometrial cancer: a view from the USA. <i>The Obstetrician and Gynaecologist</i> , 2009, 11, 199-204.	0.4	5
76	New surgical staging of endometrial cancer: 20 years later. <i>International Journal of Gynecology and Obstetrics</i> , 2009, 105, 110-111.	2.3	53
77	Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical staging. <i>Gynecologic Oncology</i> , 2008, 109, 11-18.	1.4	726
78	Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. <i>Gynecologic Oncology</i> , 2006, 101, 200-208.	1.4	121
79	Role of bcl-2 in endometrioid corpus cancer: an experimental study. <i>Anticancer Research</i> , 2006, 26, 823-7.	1.1	5
80	Endometrial cancer: can nodal status be predicted with curettage?. <i>Gynecologic Oncology</i> , 2005, 96, 594-600.	1.4	25
81	Predictors of vaginal relapse in stage I endometrial cancer. <i>Gynecologic Oncology</i> , 2005, 97, 820-827.	1.4	51
82	HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature. <i>Anticancer Research</i> , 2005, 25, 2921-7.	1.1	17
83	Endometrial carcinoma: paraaortic dissemination. <i>Gynecologic Oncology</i> , 2004, 92, 833-838.	1.4	117
84	High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. <i>Gynecologic Oncology</i> , 2004, 95, 120-126.	1.4	83
85	Molecular and histopathologic predictors of distant failure in endometrial cancer. <i>Cancer Detection and Prevention</i> , 2003, 27, 434-441.	2.1	34
86	Endometrial cancer: predictors of peritoneal failure††Supported by the Mayo Cancer Center (P30CA15083) and the Rochester Research Committee, Mayo Foundation. Presented at the 33rd Annual Meeting of the Society of Gynecologic Oncologists, Miami Beach, FL, March 16 to 20, 2002.. <i>Gynecologic Oncology</i> , 2003, 89, 236-242.	1.4	66
87	Predictors of Lymphatic Failure in Endometrial Cancer. <i>Gynecologic Oncology</i> , 2002, 84, 437-442.	1.4	109
88	Assessment of Prognostic Factors in Stage IIIA Endometrial Cancer. <i>Gynecologic Oncology</i> , 2002, 86, 38-44.	1.4	119
89	Stage IIIC Endometrioid Corpus Cancer Includes Distinct Subgroups. <i>Gynecologic Oncology</i> , 2002, 87, 112-117.	1.4	85
90	Surgical Stage I Endometrial Cancer: Predictors of Distant Failure and Death. <i>Gynecologic Oncology</i> , 2002, 87, 274-280.	1.4	118